微RNA在肌萎缩侧索硬化中的研究进展

Research advances on microRNA in amyotrophic lateral sclerosis

  • 摘要: 肌萎缩侧索硬化(ALS)是一种累及上、下运动神经元的神经系统罕见病,发病机制尚不明确,尚无有效治疗方法。近年来大量研究表明,ALS患者体内出现多种微RNA(miR)表达谱的改变,参与了ALS发病的多个关键致病环节,如错误折叠蛋白聚集、细胞凋亡和线粒体功能障碍等,具有作为诊断和判断预后生物标志物的潜力,通过利用外泌体递送miR、人工miR技术以及miR抑制剂等靶向miR的治疗策略展示出了治疗前景。文章从发病机制、生物标志物以及治疗3个方面入手,梳理了miR在ALS中的研究进展,以期为ALS的诊治提供新策略。

     

    Abstract: Amyotrophic lateral sclerosis (ALS) is a rare neurological disorder affecting both upper and lower motor neurons. Its pathogenesis remains unclear, and there is currently no effective treatment. A growing body of research indicates that patients with ALS exhibit alterations in the expression profiles of various microRNAs (miRNAs), which are involved in multiple key pathogenic mechanisms of the disease, including misfolded protein aggregation, apoptosis, and mitochondrial dysfunction. These miRNAs also hold potential as biomarkers for the diagnosis and prognosis assessment. Furthermore, therapeutic strategies targeting miRNAs—such as the delivery of miRNAs via exosomes, artificial miRNA technology, and miRNA inhibitors—have shown promise for treatment. This article reviews the research progress on miRNAs in ALS from the perspectives of pathogenesis, biomarkers, and therapy, aiming to provide new strategies for the diagnosis and treatment of ALS.

     

/

返回文章
返回